Claudia Ordonez - May 11, 2021 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role: Chief Medical Officer
Signature: /s/ Keith Regnante, Attorney-in-Fact
Stock symbol: KROS
Transactions as of: May 11, 2021
Transactions value $: -$49,670
Form type: 4
Date filed: 5/13/2021, 04:37 PM
Next filing: Jun 15, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KROS	Common Stock	Options Exercise	$480	+1K		$0.48^*	1K	May 11, 2021	Direct
transaction	KROS	Common Stock	Sale	-$50.2K	-1K	-100%	$50.15	0	May 11, 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KROS	Employee Stock Option (right to buy)	Options Exercise	$0	-1K	-1%	$0.00	99.2K	May 11, 2021	Common Stock	1K	$0.48	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2	One-quarter (1/4th) of the shares subject to the option shall vest on September 16, 2020, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.